Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.

Molecular oncology - 1 Mar 2015

Boulbes Delphine R, Arold Stefan T, Chauhan Gaurav B, Blachno Korina V, Deng Nanfu, Chang Wei-Chao, Jin Quanri, Huang Tzu-Hsuan, Hsu Jung-Mao, Brady Samuel W, Bartholomeusz Chandra, Ladbury John E, Stone Steve, Yu Dihua, Hung Mien-Chie, Esteva Francisco J

Abstract excerpt

Resistance to HER2-targeted therapies remains a major obstacle in the treatment of HER2-overexpressing breast cancer. Understanding the molecular pathways that contribute to the development of drug resistance is needed to improve the clinical utility of novel agents, and to predict the success of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Biology
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Extracellular Signal-Regulated MAP Kinases

Share to Lapatinib

Share to Mice, Nude

Share to Mutant Proteins

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 25435280
DOI: 10.1016/j.molonc.2014.10.011
PMCID: PMC4815926

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25435280-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.PMID 25435280Read ↗

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast CancerSemantic proximity Read ↗

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.Semantic proximity Read ↗

Activating HER2 mutations in HER2 gene amplification negative breast cancer.Semantic proximity Read ↗

Somatic Mutations of the HER2 Kinase Domain in Lung AdenocarcinomasSemantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

Somatic mutations of the HER2 in metastatic breast cancer.Semantic proximity Read ↗

HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.Semantic proximity Read ↗

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Semantic proximity Read ↗

HER2 mutation as an emerging target in advanced breast cancer.Semantic proximity Read ↗

Activating HER2 mutations as emerging targets in multiple solid cancersSemantic proximity Read ↗

HER2 Mutations in Non-Small Cell Lung Cancer: A Herculean Effort to Hit the Target.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.